Ignite Creation Date:
2025-12-24 @ 9:28 PM
Ignite Modification Date:
2026-01-05 @ 6:01 PM
Study NCT ID:
NCT00650832
Status:
COMPLETED
Last Update Posted:
2011-06-15
First Post:
2008-03-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.
Sponsor:
Tibotec Pharmaceuticals, Ireland
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CR006775
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None